First Industry-Sponsored Clinical Trial of a Treatment for Idiopathic Hypersomnia and Narcolepsy without cataplexy

NeuroTrials, Inc., has begun recruiting people to take part in the testing of a new treatment for idiopathic hypersomnia and narcolepsy without cataplexy. This small phase 1 study will test the safety and efficacy of a drug that is taken by mouth and swallowed. The study will also determine effective doses of the medication to treat these conditions. The researchers are looking for people who

All study-related care and study drug will be provided at no cost. Qualified people may receive compensation. If you are interested in finding out more about this study, please visit the NeuroTrials website https://www.neurotrials.com/ or https://www.facebook.com/arisestudy.

Share Post

SomnusNooze Home Page

SomnusNooze Editions/Archives
Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.